March 28, 2025 02:45 PM EDT
R&D
FDA+

FDA ap­proves Sanofi's RNAi drug for he­mo­phil­ia A and B

Max Gelman

Senior Editor

The FDA on Fri­day said it ap­proved a new RNAi-based he­mo­phil­ia treat­ment from Sanofi that the com­pa­ny li­censed from Al­ny­lam. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

Fir­ings sweep across FDA as for­mer lead­ers lament the gut­ting of drug agency

RFK Jr. has long crit­i­cized drug ads. He just slashed the FDA of­fice that reg­u­lates them

‘It’ll be a chal­lenge’: BIO chief Crow­ley ad­dress­es seis­mic FDA over­haul

Sanofi con­tin­ues its bet on R&D by poach­ing GSK’s head of de­vel­op­ment

Big am­bi­tions at Mer­ck and As­traZeneca — along with a few gi­ant pit­falls — re­shape top ranks of the R&D 15

sponsored

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

A service from the Financial Times